PLoS ONENeurosciencePeer-reviewed journal article
Antibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations
Sarah M. RuttenbergiD, Rakia DhaouiiD, Adam G. KreutzeriD, James S. NowickiD
Abstract
Anti-A{beta} antibodies are important tools for identifying structural features of aggregates of the A{beta} peptide and are used in many aspects of Alzheimers disease (AD) research. Our laboratory recently reported the generation of a polyclonal antibody, pAb2AT-L, that is moderately selective for oligomeric A{beta} over monomeric and fibrillar A{beta} and recognizes the diffuse peripheries of A{beta} plaques in AD brain tissue but does not recognize the dense fibrillar plaque cores. This antibody was generated against 2AT-L, a structurally defined A{beta} oligomer mimic composed of three A{beta}-derived {beta}-hairpins arranged in a triangular fashion and covalently stabilized with three disulfide bonds. In the current study, we set out to determine if pAb2AT-L is neuroprotective against toxic aggregates of A{beta} and found that pAb2AT-L protects human iPSC-derived neurons from A{beta}42-mediated toxicity at molar ratios as low as 1:100 antibody to A{beta}42, with a ratio of 1:25 almost completely rescuing cell viability. Few other antibodies have been reported to exhibit neuroprotective effects at such low ratios of antibody to A{beta}. ThT and TEM studies indicate that pAb2AT-L delays but does not completely inhibit A{beta}42 fibrillization at sub-stoichiometric ratios. The ability of pAb2AT-L to inhibit A{beta}42 toxicity and aggregation at sub-stoichiometric ratios suggests that pAb2AT-L binds toxic A{beta}42 oligomers and does not simply sequester monomeric A{beta}42. These results further suggest that toxic oligomers of A{beta}42 share significant structural similarities with 2AT-L. TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=108 SRC="FIGDIR/small/654602v1_ufig1.gif" ALT="Figure 1"> View larger version (16K): org.highwire.dtl.DTLVardef@d97c84org.highwire.dtl.DTLVardef@7dd416org.highwire.dtl.DTLVardef@ef072borg.highwire.dtl.DTLVardef@bfd614_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 23th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In situ generation of Aβ42 oligomers via secondary nucleation triggers neurite degeneration and synaptic dysfunction in human iPSC-derived glutamatergic neurons
Alicia González Díaz, Eleonora Sarracco, … Michele Vendruscolo·bioRxiv·Aug 30, 2024
- Amyloid-β peptide dimers undergo a random coil to β-sheet transition in the aqueous phase but not at the neuronal membrane
H. Fatafta, M. Khaled, … B. Strodel·bioRxiv·Dec 31, 2020
- Neuronal expression of S100B triggered by oligomeric Aβ peptide protects against cytoskeletal damage and synaptic loss
Joana Saavedra, Mariana Nascimento, … Isabel Cardoso·bioRxiv·Apr 4, 2025
- Aβ(1-42) tetramer and octamer structures reveal edge pores as a mechanism for membrane damage
S. Ciudad, E. Puig, … N. Carulla·bioRxiv·Sep 12, 2019
- Profiling of Aggregated Amyloid β42-induced Proteomic Alterations in KOLF2.1J Induced Pluripotent Stem Cell-derived Neurons
Benjamin Jin, Ziyi Li, … Yue Andy Qi·bioRxiv·Sep 25, 2026
- Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers
Ladan Amin, David A. Harris·Nature CommunicationsPeer-reviewed·Jun 8, 2021